2019 EULAR建议:银屑病关节炎的药物治疗(更新版)

2020-05-20 欧洲抗风湿病联盟 Ann Rheum Dis.2020 Jun;79(6):700-712.

2020年5月,欧洲抗风湿病联盟(EULAR)更新发布了银屑病关节炎的药物治疗建议,本文是对EULAR药物治疗银屑病关节炎建议的更新,共提出6条总体原则和12条推荐意见。

中文标题:

2019 EULAR建议:银屑病关节炎的药物治疗(更新版)

英文标题:

EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update

发布机构:

欧洲抗风湿病联盟

发布日期:

2020-05-20

简要介绍:

2020年5月,欧洲抗风湿病联盟(EULAR)更新发布了银屑病关节炎的药物治疗建议,本文是对EULAR药物治疗银屑病关节炎建议的更新,共提出6条总体原则和12条推荐意见。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2019 EULAR建议:银屑病关节炎的药物治疗(更新版.pdf)] GetToolGuiderByIdResponse(projectId=1, id=57e651c001908990, title=2019 EULAR建议:银屑病关节炎的药物治疗(更新版), enTitle=EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update, guiderFrom=Ann Rheum Dis.2020 Jun;79(6):700-712., authorId=0, author=, summary=2020年5月,欧洲抗风湿病联盟(EULAR)更新发布了银屑病关节炎的药物治疗建议,本文是对EULAR药物治疗银屑病关节炎建议的更新,共提出6条总体原则和12条推荐意见。, cover=https://img.medsci.cn/2020523/1590247425042_2020535.jpg, journalId=0, articlesId=null, associationId=258, associationName=欧洲抗风湿病联盟, associationIntro=null, copyright=0, guiderPublishedTime=Wed May 20 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年5月,欧洲抗风湿病联盟(EULAR)更新发布了银屑病关节炎的药物治疗建议,本文是对EULAR药物治疗银屑病关节炎建议的更新,共提出6条总体原则和12条推荐意见。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=1613, tagName=银屑病关节炎)], categoryList=[CategoryDto(categoryId=39, categoryName=皮肤性, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1613, guiderKeyword=银屑病关节炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4017, appHits=224, showAppHits=184, pcHits=925, showPcHits=3815, likes=1, shares=15, comments=7, approvalStatus=1, publishedTime=Sat May 23 23:24:16 CST 2020, publishedTimeString=2020-05-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat May 23 23:24:05 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 11:22:51 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2019 EULAR建议:银屑病关节炎的药物治疗(更新版.pdf)])
2019 EULAR建议:银屑病关节炎的药物治疗(更新版.pdf
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1078711, encodeId=14fe10e8711e2, content=好!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJUicgP739INtp7sWIPKUCvMBH2Nm2thDDTlWnBoXVnqTQuK8IgyUQQoUcByyxdMjI3948TiaupJfA/132, createdBy=124a2575636, createdName=yingxin0502, createdTime=Fri Dec 10 11:10:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009402, encodeId=958a100940252, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/23/a73e743e4c4fc915442499fe75a7a39e.jpg, createdBy=ca695079208, createdName=乔打野, createdTime=Thu Aug 19 10:44:52 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912050, encodeId=6265912050ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 01:02:19 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814160, encodeId=f62b81416074, content=标记一下 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 17:42:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808558, encodeId=c9f680855811, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83d5410816, createdName=Faye Hu, createdTime=Thu Aug 13 21:48:34 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
    2021-12-10 yingxin0502

    好!!!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1078711, encodeId=14fe10e8711e2, content=好!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJUicgP739INtp7sWIPKUCvMBH2Nm2thDDTlWnBoXVnqTQuK8IgyUQQoUcByyxdMjI3948TiaupJfA/132, createdBy=124a2575636, createdName=yingxin0502, createdTime=Fri Dec 10 11:10:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009402, encodeId=958a100940252, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/23/a73e743e4c4fc915442499fe75a7a39e.jpg, createdBy=ca695079208, createdName=乔打野, createdTime=Thu Aug 19 10:44:52 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912050, encodeId=6265912050ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 01:02:19 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814160, encodeId=f62b81416074, content=标记一下 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 17:42:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808558, encodeId=c9f680855811, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83d5410816, createdName=Faye Hu, createdTime=Thu Aug 13 21:48:34 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
    2021-08-19 乔打野

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1078711, encodeId=14fe10e8711e2, content=好!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJUicgP739INtp7sWIPKUCvMBH2Nm2thDDTlWnBoXVnqTQuK8IgyUQQoUcByyxdMjI3948TiaupJfA/132, createdBy=124a2575636, createdName=yingxin0502, createdTime=Fri Dec 10 11:10:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009402, encodeId=958a100940252, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/23/a73e743e4c4fc915442499fe75a7a39e.jpg, createdBy=ca695079208, createdName=乔打野, createdTime=Thu Aug 19 10:44:52 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912050, encodeId=6265912050ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 01:02:19 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814160, encodeId=f62b81416074, content=标记一下 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 17:42:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808558, encodeId=c9f680855811, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83d5410816, createdName=Faye Hu, createdTime=Thu Aug 13 21:48:34 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
    2020-12-30 124764c3m24(暂无昵称)

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1078711, encodeId=14fe10e8711e2, content=好!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJUicgP739INtp7sWIPKUCvMBH2Nm2thDDTlWnBoXVnqTQuK8IgyUQQoUcByyxdMjI3948TiaupJfA/132, createdBy=124a2575636, createdName=yingxin0502, createdTime=Fri Dec 10 11:10:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009402, encodeId=958a100940252, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/23/a73e743e4c4fc915442499fe75a7a39e.jpg, createdBy=ca695079208, createdName=乔打野, createdTime=Thu Aug 19 10:44:52 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912050, encodeId=6265912050ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 01:02:19 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814160, encodeId=f62b81416074, content=标记一下 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 17:42:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808558, encodeId=c9f680855811, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83d5410816, createdName=Faye Hu, createdTime=Thu Aug 13 21:48:34 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
    2020-08-27 ms4000002082197205

    标记一下 学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1078711, encodeId=14fe10e8711e2, content=好!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLJUicgP739INtp7sWIPKUCvMBH2Nm2thDDTlWnBoXVnqTQuK8IgyUQQoUcByyxdMjI3948TiaupJfA/132, createdBy=124a2575636, createdName=yingxin0502, createdTime=Fri Dec 10 11:10:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009402, encodeId=958a100940252, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/23/a73e743e4c4fc915442499fe75a7a39e.jpg, createdBy=ca695079208, createdName=乔打野, createdTime=Thu Aug 19 10:44:52 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912050, encodeId=6265912050ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 01:02:19 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814160, encodeId=f62b81416074, content=标记一下 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 17:42:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808558, encodeId=c9f680855811, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83d5410816, createdName=Faye Hu, createdTime=Thu Aug 13 21:48:34 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
    2020-08-13 Faye Hu

    学习

    0

拓展阅读

EADV:2014银屑病关节炎治疗(除外生物疗法):方法学质量评价国际指南

欧洲皮肤病与性病学会(EADV,European Academy of Dermatology and Venereology) · 2016-07-18

2018 ACR/NPF指南:银屑病关节炎的治疗

美国风湿病学会(ACR,American College of Rheumatology) · 2018-11-30

2020 ILAR建议:资源贫乏地区银屑病关节炎的管理

国外风湿免疫科相关专家小组 · 2020-01-16